利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

63 条记录 (耗时 0.027 秒)

    NOVEL CARBAMOYLGLYCINE DERIVATIVES
    2.
    发明公开
    NOVEL CARBAMOYLGLYCINE DERIVATIVES 有权
    新型氨基甲酰甘氨酸衍生物

    公开(公告)号：EP2200981A1

    公开(公告)日：2010-06-30

    申请号：EP08840109.6

    申请日：2008-10-02

    申请人： DSM IP Assets B.V.

    发明人： SARAKINOS, Georgios ,  LANGE, DE, Ben

    IPC分类号： C07D209/52 ,  C07C275/18 ,  C07C273/18 ,  C07C229/28

    CPC分类号： C07D209/52 ,  C07C275/18

    摘要： The present invention relates to carbamoylglycine derivatives, a process for the preparation of carbamoylglycine derivatives and the use of carbamoylglycine derivatives in the preparation of enantiomerically enriched α-amino acids. Furthermore, the present invention relates to the preparation of pharmaceutically active products such as perindopril and ramipril using the novel carbamoylglycine derivatives.

    摘要翻译： 本发明涉及氨基甲酰甘氨酸衍生物，制备氨基甲酰甘氨酸衍生物的方法以及氨基甲酰甘氨酸衍生物在制备对映体富集的α-氨基酸中的用途。 此外，本发明涉及使用新型氨基甲酰甘氨酸衍生物制备药物活性产物，例如培哚普利和雷米普利。

    NEW PHENYLALKYLOXY-PHENYL DERIVATIVES
    4.
    发明公开
    NEW PHENYLALKYLOXY-PHENYL DERIVATIVES 审中-公开
    新的苯基烷氧基 - 苯基衍生物

    公开(公告)号：EP1404649A1

    公开(公告)日：2004-04-07

    申请号：EP02726546.1

    申请日：2002-05-30

    申请人： AstraZeneca AB

    发明人： FÄGERHAG, Jonas ,  LI, Lanna ,  LINDSTEDT ALSTERMARK, Eva-Lotte

    IPC分类号： C07C275/18

    CPC分类号： C07C275/30

    摘要： The present invention relates to certain phenalkyloxy-phenyl derivatives of formula (I) and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

    摘要翻译： 本发明涉及式（I）的某些苯烷氧基 - 苯基衍生物及其类似物，涉及用于制备此类化合物的方法，具有与胰岛素抵抗相关的临床条件的用途，涉及其治疗用途的方法和含有它们的药物组合物。

    (METH)ACRYLATE, MONOMER COMPOSITION, DENTAL MATERIAL OBTAINED FROM SAID COMPOSITION, AND PRODUCTION METHOD THEREOF
    6.
    发明公开
    (METH)ACRYLATE, MONOMER COMPOSITION, DENTAL MATERIAL OBTAINED FROM SAID COMPOSITION, AND PRODUCTION METHOD THEREOF 审中-公开

    公开(公告)号：EP3719043A1

    公开(公告)日：2020-10-07

    申请号：EP18884379.1

    申请日：2018-11-27

    申请人： Mitsui Chemicals, Inc.

    发明人： KAKINUMA, Naoyuki

    IPC分类号： C08F20/20 ,  A61K6/087 ,  A61K6/09 ,  C07C275/14 ,  C07C275/18 ,  C07C275/24 ,  C08F20/38 ,  C08F290/06

    摘要： Provided are a monomer which can provide a cured product having both high toughness and rigidity, a monomer composition containing the monomer, the monomer composition used as a dental material monomer composition, a dental material composition containing the monomer composition or the dental material monomer composition, a cured product thereof having excellent mechanical properties, a dental material formed by curing the dental material composition, a method for producing the monomer composition, and a method for producing the dental material. A (meth)acrylate (D) is a reaction product of an amine compound (A) having two or more amino groups, an iso(thio)cyanate compound (B) having two or more iso(thio)cyanato groups, and a hydroxy (meth)acrylate compound (C) having one or more polymerizable groups.

    Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto
    7.
    发明公开
    Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto 审中-公开
    前列环素的调节剂（PG12）受体用于治疗疾病与它相关的治疗

    公开(公告)号：EP2857015A1

    公开(公告)日：2015-04-08

    申请号：EP14182803.8

    申请日：2009-03-17

    申请人： Arena Pharmaceuticals, Inc.

    发明人： Tran, Thuy-Anh ,  Chen, Weichao ,  Kramer, Bryan A. ,  Sadeque, Abu J. M. ,  Shifrina, Hanna L. ,  Shin, Young-Jun ,  Vallar, Pureza ,  Zou, Ning

    IPC分类号： A61K31/17 ,  A61K31/27 ,  C07C271/08 ,  C07C275/18 ,  A61P43/00

    CPC分类号： A61K31/195 ,  A61K31/27 ,  A61K31/325 ,  A61K31/381 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4965 ,  C07B2200/07 ,  C07B2200/13 ,  C07C271/12 ,  C07C271/28 ,  C07C275/24 ,  C07C275/28 ,  C07C275/30 ,  C07C275/34 ,  C07C309/15 ,  C07C2601/14 ,  C07D213/75 ,  C07D241/20 ,  C07D277/48 ,  C07D333/36

    摘要： The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.

    Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

    摘要翻译： 本发明涉及式的酰胺衍生物（XIIIa的）及其药物组合物做了调节PGI2受体的活性。 本发明与药物组合物的化合物及其被引导到在治疗有用的方法：肺动脉高血压（PAH）; 特发性肺动脉高压; 家族性PAH; PAH与胶原血管病，先天性心脏疾病，门静脉高压，HIV感染，摄入药物或者毒素，遗传性出血性毛细血管扩张，脾切除术，肺静脉闭塞性疾病（PVOD）或者肺毛细血管多发性血管瘤（PCH）相关联; PAH与显著静脉或毛细血管参与; 血小板聚集; 冠状动脉疾病; 心肌梗死; 短暂性脑缺血发作; 心绞痛; 中风; 缺血再灌注损伤; 再狭窄; 房颤; 在一个冠状血管成形术或旁路手术个体或在患有心房纤维性颤动的个体患有血块形成; 动脉粥样硬化; 动脉粥样硬化; 哮喘或其症状; 糖尿病相关病症：诸如糖尿病性周围神经病，糖尿病性肾病或糖尿病性视网膜病; 青光眼或者伴有异常眼内压的其它眼部疾病; 高血压; 炎症; 牛皮癣; 银屑病性关节炎; 类风湿性关节炎; 克罗恩病; 移植排斥反应; 多发性硬化; 系统性红斑狼疮（SLE）; 溃疡性结肠炎; 缺血再灌注损伤; 再狭窄; 动脉粥样硬化; 痤疮; 1型糖尿病; 2型糖尿病; 败血症; 和慢性阻塞性肺病（COPD）。

    DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR
    8.
    发明公开
    DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR 审中-公开
    尿素及相关二胺，制造方法的衍生物及其用途

    公开(公告)号：EP2041103A2

    公开(公告)日：2009-04-01

    申请号：EP07765216.2

    申请日：2007-07-10

    申请人： Galapagos SAS ,  Amgen, Inc

    发明人： DEPREZ, Pierre ,  LIVELY, Sarah ,  TEMAL-LAIB, Taoues

    IPC分类号： C07D277/48 ,  C07D277/82 ,  C07D417/12 ,  A61K31/17 ,  A61K31/426 ,  A61K31/428 ,  C07C275/18 ,  C07C275/28

    CPC分类号： C07D277/48 ,  C07C275/42 ,  C07C2601/14 ,  C07C2603/18 ,  C07D277/82 ,  C07D417/12

    摘要： Compounds of formula (I): Z is >CH-, >C=CH- or >N-, R1 and R2 are optionally substituted and are the same or different, and each represents an aryl group, a heteroaryl group, or Z, R1 and R2 form a fused ring structure of formula: in which A represents a single bond, or linking group, R3 represents hydrogen, a group selected from: -AIkCOOR, -AIkNR7R8, -AIkCONR7R8, -AIkCOR9, -AIkSO2NR10R10', -AIkOR10, and -AIkS(O)nR10, in which AIk is alkyl, R is hydrogen or alkyl, R7 and R8 each represents H, optionally substituted alkyl, alkylaminoalkyl or dialkylaminoalkyl, or CONR7R8 forms an optionally substituted heterocycle, and R10 and R10 are hydrogen atom, optionally substituted alkyl, an alkylaminoalkyl group, an optionally substituted cycle, optionally spaced by an AIk group as defined, Q represents >C=0 or >C=S, R5 is a hydrogen atom or an alkyl, alkoxy, hydroxyalkyl, alkylthio, or thioalkyl group, p is 1, 2 or 3, q is 0, 1 or 2, R6 represents an optionally substituted aryl or heteroaryl group, and salts and esters thereof, are useful as calcimimetics in therapy.

    摘要翻译： 式（I）的化合物：Z是> CH - ，> C = CH-或> N-，R 1和R 2任选地substituiertem并且它们是相同的或不同的，并且每个darstellt芳基，杂芳基，或者 Z，R 1和R 2形成下式的稠环结构：其中A代表单键，或连接基团，R 3 darstellt氢，基团选自：-AlkCOOR，-AlkNR 7 R 8，R 7 -AlkCONR 8，-AlkCOR 9，-AlkSO 2 NR 10 R 10”，-AlkOR1O，和-AlkS（O）N R 10，在其中Alk是烷基，R是氢或烷基，R 7和R 8各自darstellt H，任选 取代的烷基，烷基氨基烷基，或二烷基氨基烷基，或CONR 7 R 8组的形式在任选取代的杂环，且R“°和R 10”是氢原子，任选取代的烷基，在烷基氨基烷基，任选substituiertem循环，任选地被烷基隔开 所定义的，q darstellt> C = O或> C = S，R 5是氢原子或烷基，烷氧基，羟烷基，烷硫基，或硫代烷基，p是1，2或3，q为0，1或2个 中，R 6可选darstellt到 LY substituiertem芳基或杂芳基，和其盐和酯，如在治疗拟钙剂有用。